Broadridge announced that Amit Zavery will step down from its Board of Directors after more than seven years of service, effective after the 2026 Annual Meeting. The company nominated Srinivas D. Tallapragada, a seasoned technology executive with extensive experience at Salesforce, to join the board. Tallapragada's expertise in enterprise technology and customer-focused innovation is expected to support Broadridge's growth and technological advancement. This leadership change marks a strategic move to strengthen Broadridge's board with fresh insights in technology and innovation.
Broadridge's board changes come as 127 of 150 Technology-sector US stocks on Pluang rose today. For readers following technology stocks, here is Pluang's market snapshot as of Oct 02, 2026 02:31 WIB: Veritone Inc (VERI) fell 36.42% to USD 0.76 with a typical hold time of 13 days and 85% buy orders; Accenture plc (ACN) rose 17.87% to USD 216.13 with a typical hold time of 129 days and 48% buy orders; Synopsys, Inc. (SNPS) increased 13.26% to USD 492.60 with a typical hold time of 72 days and 37% buy orders.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
